BNP Paribas Financial Markets Boosts Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

BNP Paribas Financial Markets lifted its holdings in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 373.1% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 154,873 shares of the biopharmaceutical company's stock after buying an additional 122,136 shares during the period. BNP Paribas Financial Markets owned approximately 0.12% of Dynavax Technologies worth $1,978,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its stake in shares of Dynavax Technologies by 4.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock worth $51,948,000 after buying an additional 171,933 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Dynavax Technologies by 1.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company's stock valued at $30,077,000 after purchasing an additional 41,000 shares during the last quarter. Northern Trust Corp lifted its stake in Dynavax Technologies by 10.3% in the fourth quarter. Northern Trust Corp now owns 1,457,848 shares of the biopharmaceutical company's stock valued at $18,617,000 after purchasing an additional 135,826 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Dynavax Technologies by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company's stock valued at $14,750,000 after purchasing an additional 32,347 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in Dynavax Technologies by 0.5% in the fourth quarter. Bank of Montreal Can now owns 1,082,180 shares of the biopharmaceutical company's stock valued at $13,819,000 after purchasing an additional 5,099 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.

Wall Street Analyst Weigh In

DVAX has been the topic of several research analyst reports. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. JMP Securities dropped their price objective on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group dropped their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. Finally, William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX traded down $0.02 during trading on Friday, hitting $9.80. 1,345,654 shares of the company were exchanged, compared to its average volume of 2,220,772. The company has a market cap of $1.18 billion, a PE ratio of 54.44 and a beta of 1.26. The stock has a 50 day moving average of $11.48 and a 200 day moving average of $12.45. Dynavax Technologies Co. has a 52-week low of $9.22 and a 52-week high of $14.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). The company had revenue of $68.16 million for the quarter, compared to analysts' expectations of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, equities research analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.